Article
Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Molecular cancer therapeutics - 1 Jun 2010
Takezawa Ken, Okamoto Isamu, Tanizaki Junko, Kuwata Kiyoko, Yamaguchi Haruka, Fukuoka Masahiro, Nishio Kazuto, Nakagawa Kazuhiko
Abstract excerpt
Most non-small cell lung cancer (NSCLC) tumors with activating mutations of the epidermal growth factor receptor (EGFR) are initially responsive to first-generation, reversible EGFR tyrosine kinase inhibitors (TKI) such as gefitinib, but they subsequently develop resistance to these drugs through either acquisition of an additional T790M mutation of EGFR or amplification of the proto-oncogene MET. We have now...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.